eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

THE BOOTS COMPANY PLC

1 Thane Road West, Beeston, Nottingham, NG2 3AA
Telephone: +44 (0)1159 595 165
Fax: +44 (0)1159 592 565

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 04/01/2011
SPC Boots Slim Aid


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Potter's Boldex

Femmeherb slim aid

Tesco Slim aid

Boots slim aid


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains: -

27 mg of extract (as dry extract) from Peumus boldus Molina (5:1) (equivalent to 135 mg of Boldo)

Extraction solvent: Methanol 70% V/V

10 mg of Juglans cinerea L. (Butternut Bark)

30 mg of Taraxacum officinale Wiggers (Dandelion Root)

45 mg of extract (as dry extract) from Fucus vesiculosus L. (5:1) (equivalent to 225 mg of Fucus)

Extraction solvent: Ethanol 21% m/m

Excipients:

Each tablet contains 90 mg of Dextrose Monohydrate and is coated with sucrose. See Section 4.4 for further information

For full list of excipients see Section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Oral Tablets

A pinky orange round biconvex sugar-coated tablet.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

A herbal remedy traditionally used as an aid to slimming as part of a calorie controlled diet.


Go to top of the page
4.2 Posology and method of administration

For oral administration.

Adults: Take one or two tablets three times a day.

Elderly: Take one tablet three or four times a day.

The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

If the symptoms persist more than two weeks during the use of the medicinal product, a doctor or qualified healthcare practitioner should be consulted.

To ensure an increase in the amount of urine, adequate fluid intake is required during treatment.


Go to top of the page
4.3 Contraindications

Hypersensitivity to the active substances, including plants of the Asteraceae (Compositae) family, or any of the excipients.

Patients with:

• obstruction of the bile duct or intestinal tract

• cholangitis

• liver disease

• gallstones acute gallbladder inflammation and any other biliary disorders

• active peptic ulcer


Go to top of the page
4.4 Special warnings and precautions for use

To be used in conjunction with a calorie controlled diet

Do not exceed the stated dose.

The use in children and adolescents under 18 years of age is not recommended because data are insufficient and medical advice should be sought.

Patients with renal failure and/or diabetes, and/or heart failure should avoid taking the product because of possible complications due to hyperkalaemia.

If complaints or symptoms such as fever, dysuria, spasms or blood in the urine occur during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.

Keep all medicines out of the sight and reach of children.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

The safety of this product during pregnancy and lactation has not been established

In view of the preclinical safety data (see section 5.3), the use of this product during pregnancy and lactation should be avoided.


Go to top of the page
4.7 Effects on ability to drive and use machines

No studies on the effect on the ability to drive and use machines have been conducted.


Go to top of the page
4.8 Undesirable effects

Hypersensitivity reactions have been reported including reports of anaphylaxis with products containing Boldo. The frequency of occurrence of these reactions is not known.

Epigastric pain and hyperacidity may occur. The frequency of occurrence of these side-effects is not known..

If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted.


Go to top of the page
4.9 Overdose

No cases of overdose have been reported. Give fluids for diuresis.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

ATC Code:- CO3BX

There are no preclinical data of relevance to the prescriber, which are additional to those already included in other sections of the SPC.


Go to top of the page
5.2 Pharmacokinetic properties

No relevant pharmacokinetic data are available.


Go to top of the page
5.3 Preclinical safety data

Tests on reproductive toxicity have been performed with a dry ethanolic extract of boldo leaf and boldine administered orally to pregnant rats. Results showed anatomical alterations in the fetus and a few cases of abortion at high doses.

Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Dextrose Monohydrate

Dicalcium Phosphate

Talc (E553(b))

Magnesium Stearate (E572)

Croscarmellose

Shellac (E904)

Sucrose

Kaolin Light (E559)

Titanium Dioxide (E171)_

Red Iron Oxide 17266 (E172)

Yellow Iron Oxide 17268 (E172)


Go to top of the page
6.2 Incompatibilities

Not applicable


Go to top of the page
6.3 Shelf life

Three years.


Go to top of the page
6.4 Special precautions for storage

This medicinal product does not require any special storage instructions


Go to top of the page
6.5 Nature and contents of container

Polyethylene pot with polyethylene push-in closure: 90, 100 and 120 tablets.

Taped polyethylene bag in a cardboard carton, tape-sealed: 500 and 1000 tablets.

Polypropylene pot with HD polyethylene or polypropylene closure; 84, 100, 120 and 180 tablets.

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

There are no special precautions for disposal.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Potters Ltd

1 Botanic Court

Martland Park

WIGAN

WN5 0JZ


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00250/5200R


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

25/02/1991 / 30/01/2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT


More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/24047/SPC/


Active Ingredients/Generics

 
   dandelion root
   boldo dry extract
   fucus dry extract
   butternut bark